Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses
US10738282B2 · kind B2 · utility
1Cited by
1References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2017 |
| Grant date | Aug 11, 2020 |
| Priority date | — |
| Expiry date | Jul 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16671
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The finding that phosphatidylserine (PtdSer) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (PLSCR1) activity prevents PtdSer externalization and enables prolonged protection of vector-transduced cells from phagocytosis. Methods of inhibiting a virus vector-induced inflammatory response in tissue, methods of prolonging virus vector encoded transgene expression, and methods of modulating an inflammatory response in tissue of a subject, by administering an inhibitor of PLSCR1 are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.